/
MDGL
$507.56+$0.19 (+0.04%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.4B
23M shares
52-week range
$351.32 – $615.00
59% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$424.65
Madrigal Pharmaceuticals, Inc. Common Stock
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
www.madrigalpharma.com- Employees
- 915
- IPO / List date
- Feb 6, 2007
- HQ
- WEST CONSHOHOCKEN, PA
Held by traders on TradeandTell
No one on the platform currently holds MDGL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 71,870 | $37.6M |
| Bridgewater Associatesas of 2026-03-31 | 3,920 | $2.1M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2016-07-25 | 1-for-35reverse |
Recent trades on TradeandTell
No one on the platform has traded MDGL yet.
